MA40071A - Comprimés probiotiques bi-couche à double libération - Google Patents

Comprimés probiotiques bi-couche à double libération

Info

Publication number
MA40071A
MA40071A MA040071A MA40071A MA40071A MA 40071 A MA40071 A MA 40071A MA 040071 A MA040071 A MA 040071A MA 40071 A MA40071 A MA 40071A MA 40071 A MA40071 A MA 40071A
Authority
MA
Morocco
Prior art keywords
different
probiotic
probiotics
gastrointestinal tract
dual release
Prior art date
Application number
MA040071A
Other languages
English (en)
French (fr)
Inventor
Anthony Blanch
Timothy Gamble
Original Assignee
Probi Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Usa Inc filed Critical Probi Usa Inc
Publication of MA40071A publication Critical patent/MA40071A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA040071A 2014-07-01 2015-06-29 Comprimés probiotiques bi-couche à double libération MA40071A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462019717P 2014-07-01 2014-07-01

Publications (1)

Publication Number Publication Date
MA40071A true MA40071A (fr) 2016-01-07

Family

ID=55019868

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040071A MA40071A (fr) 2014-07-01 2015-06-29 Comprimés probiotiques bi-couche à double libération

Country Status (17)

Country Link
US (1) US10799541B2 (OSRAM)
EP (1) EP3164145A4 (OSRAM)
JP (1) JP2017520577A (OSRAM)
KR (1) KR20170021350A (OSRAM)
CN (1) CN106535909A (OSRAM)
AP (1) AP2016009641A0 (OSRAM)
AU (1) AU2015284425B2 (OSRAM)
BR (1) BR112016031000B1 (OSRAM)
CA (1) CA2951739C (OSRAM)
CL (1) CL2016003306A1 (OSRAM)
MA (1) MA40071A (OSRAM)
MX (1) MX383492B (OSRAM)
PH (1) PH12016502463A1 (OSRAM)
RU (1) RU2736823C2 (OSRAM)
SG (1) SG11201610250WA (OSRAM)
WO (1) WO2016003870A1 (OSRAM)
ZA (1) ZA201608433B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3048361B1 (fr) * 2016-03-01 2020-12-18 Biose Compositions pour le traitement des candidoses
CN108066296B (zh) * 2016-11-11 2020-11-17 南京益恒寿生命科技有限公司 一种生物学活性组分结肠靶向组合物及其应用
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
EP3735224A4 (en) * 2018-01-05 2021-11-03 Nubyiota LLC COMPOSITIONS WITH CO-SELECTED MICROBIOTA AND METHOD OF USING THEREOF
EP3556226B1 (de) * 2018-04-20 2021-01-20 Raab Vitalfood GmbH Komplex-synbiotikum zum aufbau einer gesunden darmflora
WO2019242839A1 (en) 2018-06-18 2019-12-26 Probi Ab Lactobacillus plantarum compositions and uses thereof
MX2020013439A (es) 2018-06-18 2021-05-12 Probi Ab Composiciones probioticas y usos de las mismas.
EP3870691A4 (en) 2018-09-13 2022-09-07 Xbiome Inc. METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL AND INFLAMMATORY DISORDERS
WO2020181096A1 (en) * 2019-03-05 2020-09-10 The Texas A&M University System Combinations of tannase and probiotic formulations and methods of use for improving tannin metabolism
GB201905386D0 (en) 2019-04-16 2019-05-29 Probi Ab Probiotic compositions and uses thereof
GB201908154D0 (en) 2019-06-07 2019-07-24 Probi Ab Lactobacillus compositions and uses thereof
GB201908706D0 (en) 2019-06-18 2019-07-31 Probi Ab Lactobacillus compositions and uses thereof
CN110251474B (zh) * 2019-07-15 2022-01-07 北京工商大学 一种淀粉基大肠靶向双层益生菌片的制备方法
CN117159485A (zh) * 2023-08-11 2023-12-05 江中药业股份有限公司 一种益生菌香口丸及其制备方法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6037953A (ja) 1983-08-11 1985-02-27 Herusu Eido:Kk カルシウムを主成分とする栄養補助食品
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
ATE214597T1 (de) 1997-12-19 2002-04-15 Merck Patent Gmbh Mehrschichttablette enthaltend probiotische mikroorganismen wie z.b. lactobacilli oder bifidobakterien
JP2000302694A (ja) * 1999-04-16 2000-10-31 Fuyuki Mitsuyama 医食兼用物質
US6696057B1 (en) 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
US20020044926A1 (en) 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
US20030118547A1 (en) * 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
ATE340563T1 (de) * 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
EP1151673A3 (en) 2000-05-03 2002-01-02 Societe Des Produits Nestle S.A. Confectionery product having a filling
EP1345613B1 (en) 2000-12-18 2008-04-09 Probio Health Probiotic compounds derived from lactobacillus casei strain ke01
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
EP1228769A1 (de) 2001-02-02 2002-08-07 Jörg-Peter Prof. Schür Symbiontisches Regenerativum
EP1392245A2 (en) 2001-04-05 2004-03-03 Universite Laval Process for making protein delivery matrix and uses thereof
US6627220B2 (en) 2001-07-13 2003-09-30 Scolr, Inc. Tablets containing heat sensitive materials and method for forming thereof
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
PT1429802E (pt) * 2001-09-28 2013-01-24 Tntgamble Inc Sistema de entrega para componente biológico
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
EP1344458A1 (en) 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
US20030175295A1 (en) 2002-03-15 2003-09-18 Richard Ticktin Composition and method for reducing odors from metabolic processes
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
GB0212975D0 (en) 2002-06-06 2002-07-17 Mars Uk Ltd Mammalian animal composition
TW200404544A (en) 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
US20050266069A1 (en) 2002-09-06 2005-12-01 Simmons Donald L Stable probiotic microsphere compositions and their methods of preparation
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
US7105336B2 (en) 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
ES2365012T3 (es) 2002-11-12 2011-09-20 Elan Pharma International Limited Formas farmacéuticas sólidas de desintegración rápida que no son friables y que comprenden pululano.
WO2004087109A1 (ja) 2003-03-27 2004-10-14 Hisamitsu Pharmaceutical Co., Inc. 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
US7025998B2 (en) 2003-05-30 2006-04-11 Rotta Research Laboratorium S.P.A. Phytoestrogens and probiotic for women's health
JP3818319B2 (ja) 2003-08-21 2006-09-06 大塚製薬株式会社 粘膜免疫賦活作用を有する乳酸菌
GB0330009D0 (en) * 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
WO2005074976A1 (en) 2004-02-09 2005-08-18 Transfert Plus Société En Commandite Composition comprising polymeric material and uses thereof
US20050260181A1 (en) 2004-03-05 2005-11-24 Immunopath Profile, Inc. Compositions and methods for tissue repair
US7854927B2 (en) 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
GB0410785D0 (en) 2004-05-14 2004-06-16 Glycologic Ltd Improved prebiotic
WO2005115341A2 (en) 2004-05-27 2005-12-08 Advanced Bionutrition Corporation Microparticles for oral delivery
DE102004026706A1 (de) 2004-05-28 2005-12-15 Merck Patent Gmbh Orale Darreichungsform enthaltend probiotische Bakterien
US20060062773A1 (en) 2004-09-21 2006-03-23 The Procter & Gamble Company Compositions for maintaining and restoring normal gastrointestinal flora
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
EP1885207B1 (en) 2005-05-18 2011-07-06 DSM IP Assets B.V. Compositions for enteral application of microorganisms
US9072784B2 (en) 2005-09-29 2015-07-07 Merck Patent Gmbh Method for stabilising pharmaceutical administration forms comprising microorganisms
US7982066B2 (en) 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
AU2005339139A1 (en) 2005-12-14 2007-06-21 Oxthera, Inc. Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
US20070184111A1 (en) 2006-02-03 2007-08-09 Pharmavite Llc Hybrid tablet
WO2008076975A1 (en) 2006-12-18 2008-06-26 Advanced Bionutrition Corporation A dry food product containing live probiotic
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
US20080171085A1 (en) 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
US8066986B2 (en) * 2007-02-01 2011-11-29 Master Supplements, Inc. Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms
WO2008122965A2 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
WO2009035496A1 (en) 2007-08-03 2009-03-19 Shaklee Corporation Nutritional dosage unit
WO2009037264A2 (en) 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
US9078824B2 (en) 2007-09-24 2015-07-14 The Procter & Gamble Company Composition and method of stabilized sensitive ingredient
US20110223248A1 (en) 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
CA2712207A1 (en) 2008-01-24 2009-07-30 Nestec S.A. Capsule containing nutritional ingredients and method of delivery of a nutritional liquid from the capsule
EP2280713A1 (en) 2008-05-01 2011-02-09 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
WO2009149149A1 (en) 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
RU2011100746A (ru) * 2008-06-24 2012-07-27 Вм. Ригли Дж. Компани (Us) Композиция жевательной резинки с пробиотиком и способ ее производства
CA2737247C (en) 2008-09-15 2016-10-11 Labopharm Inc. Starch-based microparticles for the release of agents disposed therein
JP2012508773A (ja) * 2008-11-14 2012-04-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 低いｐＨでの難水溶性のイオン化活性薬剤の制御放出のための固体組成物およびその使用方法
GB0900551D0 (en) 2009-01-14 2009-02-11 Horton Richard Ingestible compositions and processes of preparation
DK2381799T3 (en) 2009-01-27 2018-10-22 Probiotical Spa PROBIOTIC SUPPLEMENT WITH CHOCOLATE TASTE
KR20170053733A (ko) 2009-02-24 2017-05-16 리터 파마슈티컬즈 인코오포레이티드 프리바이오틱 제제 및 사용 방법
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
AU2010221209C1 (en) 2009-03-06 2015-09-03 Tamarisk Technologies Group, L.L.C. Microencapsulated bioactive agents for oral delivery and methods of use thereof
JP2012520325A (ja) 2009-03-13 2012-09-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プレバイオティックオリゴ糖
US20100330151A1 (en) 2009-06-25 2010-12-30 Mary Elaine Freeland Method of Promoting Gastrointestinal Health Using a Combination of a Probiotic Microorganism and Chocolate
WO2011009848A2 (en) * 2009-07-20 2011-01-27 Bracco Spa Therapeutic use of probiotics
EP2459203B1 (en) 2009-07-30 2018-10-31 DuPont Nutrition Biosciences ApS Lactic acid bacteria and bifidobacteria for treating endotoxemia
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
MX348611B (es) 2009-12-31 2017-06-21 Milton Trachtman Ira Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
KR101143997B1 (ko) 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법
WO2011130487A1 (en) 2010-04-14 2011-10-20 Ganeden Biotech, Inc. Probiotic confection and lipid compositions
WO2011146715A1 (en) 2010-05-19 2011-11-24 North Carolina State University Compositions and methods for the delivery of therapeutic peptides
US20140154312A1 (en) 2010-09-17 2014-06-05 Monica Gulati Oral targetted drug delivery system
WO2012103411A2 (en) * 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
PL2685994T3 (pl) 2011-03-17 2016-05-31 Probiotical Spa Bakterie probiotyczne wykazujące aktywność przeciwutleniającą i ich zastosowanie
WO2012154738A1 (en) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition and method to improve intestinal health
US9308227B2 (en) 2011-05-16 2016-04-12 Organobalance Medical Ag Lactic acid bacteria and compositions containing them against bacterial colds
CN202427429U (zh) 2012-01-09 2012-09-12 北京大北农科技集团股份有限公司 一种多层微囊制备设备
US20130295227A1 (en) 2012-05-01 2013-11-07 Robbert H. ter Haar Composition Comprising a Sensitive Ingredient
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US20140112985A1 (en) 2012-10-22 2014-04-24 Polonez Therapeutics Llc Method of prevention and treatment of clostridium difficile infection
WO2014130540A1 (en) * 2013-02-22 2014-08-28 The Regents Of The University Of California Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
CA2904389C (en) * 2013-03-14 2018-09-18 Jerome J. Schentag Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents

Also Published As

Publication number Publication date
EP3164145A1 (en) 2017-05-10
MX2016016773A (es) 2017-06-30
AU2015284425B2 (en) 2021-04-01
CA2951739A1 (en) 2016-01-07
BR112016031000A2 (OSRAM) 2017-08-22
US20170100442A1 (en) 2017-04-13
CA2951739C (en) 2023-09-19
ZA201608433B (en) 2023-05-31
CL2016003306A1 (es) 2017-06-09
SG11201610250WA (en) 2017-01-27
WO2016003870A1 (en) 2016-01-07
EP3164145A4 (en) 2018-01-17
US10799541B2 (en) 2020-10-13
AP2016009641A0 (en) 2016-12-31
RU2017102952A (ru) 2018-08-01
RU2736823C2 (ru) 2020-11-20
RU2017102952A3 (OSRAM) 2019-02-01
PH12016502463A1 (en) 2017-04-10
AU2015284425A1 (en) 2017-01-05
BR112016031000B1 (pt) 2022-01-25
CN106535909A (zh) 2017-03-22
MX383492B (es) 2025-03-04
JP2017520577A (ja) 2017-07-27
KR20170021350A (ko) 2017-02-27

Similar Documents

Publication Publication Date Title
PH12016502463A1 (en) Bi-layer dual release probiotic tablets
IL222268A (en) Preserved pyrollo-pyridines, containing pharmaceutical preparations, combined preparations containing them and their use in the preparation of medicines
HK1218560A1 (zh) 组成与方法
WO2012035429A3 (en) Remotely controlled drug delivery systems
MY166518A (en) Nanocapsules containing microemulsions
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
PH12012502083A1 (en) Manufacturing of active-free granules and tablets comprising the same
IL261982A (en) A prophylactic and therapeutic preparation based on peroxaphthalate, especially a pharmaceutical preparation
MX2014012164A (es) Composiciones a base de probioticos y un complejo de polen de abejas/arcilla, su preparacion y sus usos en nutricion y en terapeutica.
HK1201477A1 (en) Pharmaceutical composition of omeprazole
LT3003383T (lt) Kieta kompozicija, skirta peroraliniam vartojimui, turinti ibandrono rūgštį arba jos farmaciniu požiūriu priimtiną druską ir vitaminą d
IL273704A (en) Pharmaceutical bilayer tablet formulations
IL272806B1 (en) The history of boronic acid, its preparation and pharmaceutical preparations containing it
PH12016500693B1 (en) Slow-release solid oral compositions
IL213671A (en) Pharmaceutical preparations containing alglitazar, a process for their preparation and use for the preparation of medicines
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
MX2022013541A (es) Composiciones de acido gamma-poliglutamico y zinc.
WO2014016277A3 (de) Vitaminzubereitung
EP2863899B8 (en) Formulations for the preparation of immediate-release tablets for oral use containing low-dose mifepristone for the treatment of endometriosis, tablets thus obtained and their preparation process
TN2015000156A1 (en) Dispersible tablet
EP3065737A4 (en) Oral pharmaceutical form for preventing vascular diseases, tablet as pharmaceutical form and gelatin capsule as pharmaceutical form
WO2013127539A3 (de) Pharmazeutische formulierung enthaltend flupirtin
HK1233921A1 (en) Bi-layer dual release probiotic tablets
SA515360445B1 (ar) قرص قابل للتشتيت
CN302425484S (zh) 药片